Main Article Content
The present study, totally 2710 samples taken, number of Acinetobacter positive cases were 58 (2.1%). Out of total 775, 1699 and 236 samples of wound/pus, urine and sputum samples number of Acinetobacter isolated were 36 (27.1 %), 16(13%) and 6(12.5 %) respectively. Out of total 58 Acinetobacter positive cases, maximum was from wound/pus (36) and least was from sputum (6) samples. A. baumannii species was the maximum (34) out all the samples, compared to other species. Out of these 34 cases of A. baumannii, maximum positive cases were isolated from wound (22) and least from sputum (2) samples. Of the total 58 Acinetobacter isolated, maximum was from ICU (20cases) and least from Gynaecology and Urology departments (2cases each). Out of total 58 Acinetobacter positive cases, more number of cases was between the age group 31-45 years and least between 0-15 years. 30 cases (52%) were males and 28 (48%) were females. In the whole year maximum isolation of Acinetobacter was between the months of July to September. Out of 16 antimicrobials tested, for 34 A. bowmannii isolates (by Kirby Buer Disk Diffusion method and vitek for colistin), maximum resistance was for Ciprofloxacin (97%) and 100% susceptibility was seen for Colistin, Tobramycin, Minocycline and Tigecycline. Acinetobacterbowmannii showed more resistant to antibiotics compared to other species (A. lwoffii, Acalcoaceticus, A.hemolyticus). 21 isolates (61.8%) of Acinetobacterbowmannii was multi drug resistant and mainly from ICU patients i.e., 15 isolates (71.4%). No extensively drug resistant and pan drug resistant strains were found in this study. Out of 16 antimicrobials tested for all 58 Acinetobacter isolates (by Kirby Buer Disk Diffusion method and vitek for colistin), maximum resistance was for Ciprofloxacin (82.8%) and 100% susceptibility was seen for Colistin, Tobramycin, Minocycline and Tigecycline.